Strategic Submissions: An Analysis of Supplemental Drug Approvals
Journal of Economics & Management Strategy · 14.06.2026
DOI: 10.1111/jems.70038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Economics & Management Strategy, online erschienen am 14.06.2026. Verfasst von Pierre Dubois und 2 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Agence Nationale de la Recherche.
Abstract (Originalsprache)
Off‐label use regulation has the potential to change pharmaceutical firms' behavior and—consequently—affect patient welfare. We investigate the impact of changes in off‐label regulation on pharmaceutical firms' behavior in seeking formal marketing approval for supplemental uses. In 2012, a US court decision protected truthful off‐label promotion, providing pharmaceutical companies more leeway to promote off‐label uses of their drug. Using a unique data set of pharmaceutical firms' research and development projects, we exploit this regulatory change to understand how firms react to government policies. Results demonstrate that the hazard of approval declined for supplemental uses, relative to original uses, after the policy change. Patent protection, potential market size, and competition are also important determinants of the hazard of approval. These results have implications not only for innovation policy but for the creation of high‐quality data for certain indications.
Förderung
- Agence Nationale de la Recherche
Zitieren
APA
Dubois, P., Gentry, E. P., & Tunçel, T. (2026). Strategic Submissions: An Analysis of Supplemental Drug Approvals. Journal of Economics & Management Strategy. https://doi.org/10.1111/jems.70038
Vancouver
Dubois P, Gentry EP, Tunçel T. Strategic Submissions: An Analysis of Supplemental Drug Approvals. Journal of Economics & Management Strategy. 2026. doi:10.1111/jems.70038
BibTeX
@article{Dubois2026,
author = {Dubois, Pierre and Gentry, Elissa Philip and Tunçel, Tuba},
title = {Strategic Submissions: An Analysis of Supplemental Drug Approvals},
journal = {Journal of Economics & Management Strategy},
year = {2026},
doi = {10.1111/jems.70038}
}
EUVIMED